Type 2 Inflammation Biologic (Anti-IL-5R) from AstraZeneca.
Fasenra targets the IL-5 receptor on eosinophils, leading to rapid and near-complete depletion of eosinophils. The convenient every-eight-week dosing after the loading phase is a meaningful advantage for many patients with severe eosinophilic asthma.
Fasenra is FDA-approved for the following indications:
Fasenra is administered subcutaneously every four weeks for the first three doses, then every eight weeks for maintenance. Both in-office and self-administered options are available.
The manufacturer offers a patient support program — AZ&Me / Access 360 — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.astrazeneca-us.com/patients/access-360.html.
Treatment with Fasenra is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. This is a subcutaneous self-administered medication. After prior authorization, the prescription is sent to a specialty pharmacy that ships the medication directly to the patient. A manufacturer-sponsored nurse or office-based training visit is typically arranged for the first dose so patients are confident with self-administration before continuing at home.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.fasenra.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Fasenra is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.